We boost the pharmaceutical industry in Brazil.
We actively participate in public consultations promoted by Anvisa and collaborate with suggestions in various areas, contributing to the improvement and strengthening of health policies that impact the pharmaceutical sector.
We act as intermediaries between the pharmaceutical sector and government bodies, representing the interests of our members and promoting a technical dialog with regulatory agencies, ministries and parliamentarians.
We represent the sector in various spaces for debate and decision-making. The entity maintains constant and effective communication with health organizations, trade associations and other stakeholders.
We monitor and report cases of undue extension of patent terms to government bodies, and we also take legal action to combat these practices.
Generic drugs: promoting access for a quarter of a century.
In 2030 we will reach
Generic drugs: promoting access for a quarter of a century.
In 2030 we will reach
billion in savings
billion in savings
of known diseases
of medicines from the Popular Pharmacy Program
of sales in Brazil
is the average discount
is the projection of
of patients
We are 8th country
with the highest number of biosimilarsOn the global stage, the organic market grows at a rate close to 14% per year. In Brazil, these drugs already account for 30% of the pharmaceutical sector, with the prospect of continued expansion in the coming years.
Trata-se do Fiprima (filgrastim), um biossimilar indicado para ajudar o organismo a produzir mais neutrófilos, um tipo de glóbulo branco essencial para combater infecções.
of biological product registrations with Anvisa (515) are biosimilars - 70 in total.
of the biological active ingredients (226) are already available as biosimilars - 18 in all.
of the presentations of biological medicines (604) correspond to biosimilars - 80 in total.
The Brazilian medicines market had a turnover of approximately R$ 178 billion in 2023, equivalent to US$ 35.6 billion.
Investment: what does the country's industry do?
411 pharmaceutical companies = 28% international and 72% national. Of these, more than 100 laboratories market generics in the country.
Nationally-owned companiesaccount for 51% of turnover and 81% of cash registers.
Meanwhile, international companies accounted for 49% of turnover and 9% of boxes sold.
+ 91,000 direct jobs
+ 800,000 indirect jobs
- Access.
- Innovation.
- Regulation.
- Industrial Property.
- Legislation.
- Public Policy.
- Medicines.
- Biosimilars.
- Generic.
- Biological.
- Synthetics.
- Immunology.
Our History
1999
2000
2001
2004
2021
2023
2024
